newsfilter
← Latest News
GlobeNewswire·

Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate

CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it